ANTIBODY THERAPEUTICS XCHANGE
2024
San Diego, February 26

Welcome to hubXchange’s San Diego Antibody Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS:
Handlery Hotel San Diego,
950 Hotel Circle North,
San Diego CA 92108

SNAPSHOTS OF DISCUSSION TOPICS

Track 1: Target Selection

Computational approach for target selection
How to ensure target specificity to avoid unintended interactions with other proteins and molecule

Track 2: Lead Identification & Optimization

Challenging membrane antibody targets: Brainstorming in-parallel in vivo and in vitro methodologies to identify rare and precious functional Ab candidates
One size doesn’t fit all: Key considerations for successful therapeutic antibody discovery for various modalities and indications

Track 3: Formats & Scaffolds

Fc engineering for improved antibody druggability
Considerations for CAR-T/ CAR-NK cell binder format designs during screening and selections

Track 4: Bi/Multi-Specifics

Developing bispecifics targeting novel targets
Immuno-oncology tumour-specific approach through multispecific therapeutics

Track 5: Emerging Technologies

Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration
Using AI, AlphaFold and ML methods for therapeutics discovery and optimization

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Different criteria for target selection depending on the type of biologic modality

Key issues in target selection:

therapeutic index,
resistance mechanisms,
OMICs platforms for target selection

Snezana Milutinovic, Associate Director, Boundless Bio

Milutinovic has 20 years of experience in diverse oncology research areas and has been involved in driving several biologic and small molecule therapeutics into FIH studies. Deep understanding and experience in evaluating different target classes and resistance mechanisms has enabled her to identify strongly synergistic drug combinations and influence clinical strategies for patients with unmet needs.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:50– 14:20

1-2-1 Meetings/Networking Break

14:20 – 14:50

1-2-1 Meetings/Networking Break

14:50 – 15:20

Poster Presentation

15:30 – 16:00

1-2-1 Meetings/Networking Break

16:05 – 17:05

Computational approach for target selection (Topic TBC)

Sudhakar Chintharlapalli, Senior Director, Pfizer

17:05– 18:05

Drinks-Canape Reception

Lead Identification & Optimization

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Challenging membrane antibody targets: Brainstorming in-parallel in vivo and in vitro methodologies to identify rare and precious functional Ab candidates

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:50 – 14:20

1-2-1 Meetings/Networking Break

14:20 – 14:50

1-2-1 Meetings/Networking Break

14:50 – 15:20

Poster Presentation

15:30 – 16:00

1-2-1 Meetings/Networking Break

16:05 – 17:05

Discovery of pharmacollogically active antibodies that target challenging membrane proteins

How can we ensure the presentation of folded membrane protein antigens during immunization and screening?
How to maximize the identification of hit diversity and maximize the potential of recovering functionally active antibodies
What new antibody/alternative formats are being used to functionally target GPCRs, Ion Channels and other tough to drug membrane protein targets?

Chris Roth, Vice President of Research, Abilita Therapeutics, Inc. TBC

Christopher Roth, PhD is the Vice President of Research at Abilita Therapeutics, where he is leading multiple therapeutic antibody discovery programs targeting GPCRs and ion channels for the treatment of cancer and pain. Prior to joining Abilita, Chris was a member of the founding scientific team at Receptos, where he invented novel GPCR engineering technologies that underpinned the structure-based discovery platform. Chris earned his PhD in the laboratory of Ray Stevens at The Scripps Research Institute, where he was a member of the team that solved seminal high-resolution GPCR crystal structures and developed core approaches used throughout the field today.

17:05– 18:05

Drinks-Canape Reception

Formats & Scaffolds

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Multi-specific agonists for Immuno-oncology. Challenges and opportunities in protein engineering.

What are the design challenges for multi-specific antibodies and how can we overcome those?
The role of precise affinity-tuning
Cell targeting and the issue of on-target off-cell type activity
Choice of the right TAA

Libin Cui, Chief Executive Officer, Akeagen

Libin Cui, PhD, is the founder and CEO of Akeagen Inc, a biotech company that develop CaMouse TM mice for single domain antibody discovery.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:50 – 14:20

1-2-1 Meetings/Networking Break

14:20 – 14:50

1-2-1 Meetings/Networking Break

14:50 – 15:20

Poster Presentation

15:30 – 16:00

1-2-1 Meetings/Networking Break

16:05 – 17:05

Optimisation of complex antibody-based modalities using in silico and lab-based approaches

Jonah Rainey, Senior Director, Antibody Engineering, Eli Lilly and Company

17:05– 18:05

Drinks-Canape Reception

Bi/Multi-Specifics

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Multi-specific agonists for Immuno-oncology. Challenges and opportunities in protein engineering.

What are the design challenges for multi-specific antibodies and how can we overcome those?
The role of precise affinity-tuning
Cell targeting and the issue of on-target off-cell type activity
Choice of the right TAA

Dirk Zajonc, Head of Antibody Engineering, Protillion Biosciences

Dr. Zajonc has more than 20 years of experience in structural immunology in both academia and industry. His expertise includes both small molecule design (altered glycolipid ligands) to modulate NKT cell responses, as well as large molecule drug development in immuno-oncology. Before joining Protillion, Dr. Zajonc was leading antibody discovery and protein engineering efforts for early-stage immuno-oncology projects at Pfizer La Jolla. He published over 100 peer-reviewed papers and applied for several patents.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:50 – 14:20

1-2-1 Meetings/Networking Break

14:20 – 14:50

1-2-1 Meetings/Networking Break

14:50 – 15:20

Poster Presentation

15:30 – 16:00

1-2-1 Meetings/Networking Break

16:05 – 17:05

Developing therapies to target multiple immune pathways

What are the current approaches used to targeting mulitple immune pathways?
What are the key challenges (eg. CMC, trial design) in developing multi-targeting therapeutics for immune-mediated diseases?
What targets are best positioned for multi-targeting approaches?

Michael Howell, Chief Scientific Officer, Zura Bio

Dr. Michael Howell currently serves as the Chief Scientific Officer and Head of Translational Science at Zura Bio. He is also the Founder of Mountaineer Biosciences and Co-Founder of Galileo Biosystems. Dr. Howell is an immunologist with more than 25 years of experience in research and development and has previously led teams dedicated to the discovery of novel therapies and the integration of precision as well as personalized medicine approaches into clinical development. His efforts have led to the approval of multiple therapies, novel diagnostic approaches to patient treatment, and have been highlighted in more than 60 publications and numerous patents.

17:05– 18:05

Drinks-Canape Reception

Emerging Technologies

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation

9:05 – 10:05

Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration (Topic TBC)

Immunotherapy and solid cancer
Persistence of CARs
Immune memory cells

Anindya Bagchi, Co-Founder, Styx Biotechnologies Incorporated

Anindya Bagchi is a faculty/Associate Professor at the Sanford Burnham Prebys Medical Discovery Institute and a co-founder of Styx Biotechnologies Inc. Her research is focused on bringing new, effective personalised therapies for cancer patients.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Sponsor-led Roundtable

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation

13:50– 14:20

1-2-1 Meetings/Networking Break

14:20 – 14:50

1-2-1 Meetings/Networking Break

14:50 – 15:20

Poster Presentation

15:30 – 16:00

1-2-1 Meetings/Networking Break

16:05 – 17:05

Using AI, AlphaFold and ML methods for therapeutics discovery and optimization

17:05– 18:05

Drinks-Canape Reception

ANTIBODY THERAPEUTICS XCHANGE 2024 San Diego, February 26

SNAPSHOTS OF DISCUSSION TOPICS

Full Xchange Agenda

Target Selection

Partners

ANTIBODY THERAPEUTICS XCHANGE
2024
San Diego, February 26